



July 24, 2007. Artemisia BioMedical Awarded Washington Technology Center Research Funding.

Artemisia BioMedical, Inc. (Newcastle, WA) was one of five companies awarded state funding from the Washington Technology Center (Seattle, WA) for innovative commercial technology applications developed in partnership with Washington State researchers. The Company and University of Washington researchers Tomikazu Sasaki, Henry Lai and Narendra Singh will use the Research and Technology Development funding for further development of targeted artemisinin-based technologies for cancer therapy.

The company-researcher team was awarded \$100,000 in from Washington State to further develop their project entitled "Preclinical Development of Artemisinin Trioxane Dimer-Peptide Conjugates as Targeted Cancer Therapeutics". In their research and technology development project, Artemisia BioMedical and the University of Washington research team will develop and study new synthetic therapeutic agents that deliver artemisinin, a malaria drug with potent anti-cancer effects, and iron as one package selectively into cancer cells. The objective of their research will be the creation of more highly selective, effective and safer therapeutics for people suffering from cancer with minimal side-effects. This WTC-supported technology holds promise as a breakthrough for the treatment of many types of human cancer.

Contact:

Artemisia BioMedical, Inc

Woerner P. Meehan, PhD

President

Tel: (206) 499-8432

Email: pmeehan@artbiomedical.com